ACTIV-1 abatacept, 2020 NCT04593940
abatacept vs. placebo
COVID-19 severe or critically
Fakharian, 2021 IRCT20151227025726N2
adalimumab vs. standard of care
COVID-19 severe or critically
Ming Zhong, 2020 ChiCTR2000029851
alpha lipoic acid vs. standard of care
COVID-19 severe or critically
Ana-COVID (Huet), 2020
anakinra vs. control
COVID-19 severe or critically
Kooistra, 2020
anakinra vs. standard of care
COVID-19 severe or critically
ATCO, 0 NCT04332666
angiotensin-(1-7) vs. placebo
COVID-19 severe or critically
ChiCTR2000029806 (camrelizumab), 0 ChiCTR2000029806
anti-PD-1 antibody vs. standard of care
COVID-19 severe or critically
COPERNICO, 0 NCT04335305
anti-PD-1 antibody vs. tocilizumab
COVID-19 severe or critically
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 NCT02735707
anticoagulant, curative dose vs. anticoagulant, prophylactic dose
COVID-19 severe or critically
COVID-PACT, 2022
anticoagulant, curative dose vs. anticoagulant, prophylactic dose
COVID-19 severe or critically
Tang, 2020
anticoagulant, prophylactic dose vs. control
COVID-19 severe or critically
INSPIRATION, 2021 NCT04486508
anticoagulation, intermediate prophylactic dose vs. anticoagulant, prophylactic dose
COVID-19 severe or critically
INSPIRATION-S, 2022 NCT04486508
Atorvastatin vs. placebo
COVID-19 severe or critically
ACTIV-3 Critical Care, 2022 NCT04843761
aviptadil vs. placebo
COVID-19 severe or critically
Duke University azithromycin, 2020 NCT04335552
azithromycin vs. standard of care
COVID-19 severe or critically
COALITION II Covid-19 Brazil (Furtado), 2020 NCT04321278
azithromycin vs. standard of care
COVID-19 severe or critically
COV-BARRIER (critically ill), 2022 NCT04421027
baricitinib vs. placebo
COVID-19 severe or critically
Tziolos, 2021
baricitinib vs. standard of care
COVID-19 severe or critically
NCT04445935, 0 NCT04445935
Bivalirudin vs. standard of care
COVID-19 severe or critically
CAN-COVID, 2020 NCT04362813
canakinumab vs. placebo
COVID-19 severe or critically
NCT04317040, 0 NCT04317040
CD24Fc vs. placebo
COVID-19 severe or critically
ACTIV-1 cenicriviroc, 2020 NCT04593940
cenicriviroc vs. placebo
COVID-19 severe or critically
Karolyi, 2020
chloroquine and derivatives vs. lopinavir/ritonavir
COVID-19 severe or critically
Duke university (Hydroxychloroquine), 2020 NCT04335552
chloroquine and derivatives vs. standard of care
COVID-19 severe or critically
NCT04343989, 0 NCT04343989
clazakizumab vs. placebo
COVID-19 severe or critically
COLCHIVID, 2021 NCT04367168
colchicine vs. placebo
COVID-19 severe or critically
Brunetti, 2020
colchicine vs. standard of care
COVID-19 severe or critically
FORCE , 0 NCT04371367
complement inhibitors vs. standard of care
COVID-19 severe or critically
Duan, 2020
convalescent plasma treatment vs. control
COVID-19 severe or critically
Sean, 2020
convalescent plasma treatment vs. control
COVID-19 severe or critically
Hegerova, 2020
convalescent plasma treatment vs. control
COVID-19 severe or critically
Joyner, 2020 NCT04338360
convalescent plasma treatment vs. convalescent plasma treatment
COVID-19 severe or critically
Gonzales, 2021 NCT04381858
convalescent plasma treatment vs. immunoglobulin therapy
COVID-19 severe or critically
ILBS-COVID-02 (Bajpai M), 2020 NCT04346446
convalescent plasma treatment vs. placebo
COVID-19 severe or critically
O’Donnell, 2021 NCT04359810
convalescent plasma treatment vs. placebo
COVID-19 severe or critically
NCT04400058, 0 NCT04400058
convalescent plasma treatment vs. placebo
COVID-19 severe or critically
PlasmAr, 2020 NCT04344535
convalescent plasma treatment vs. placebo
COVID-19 severe or critically
PLASM-AR, 0 NCT04383535
convalescent plasma treatment vs. placebo
COVID-19 severe or critically
ChiCTR2000030627, 0 ChiCTR2000030627
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
CP-COVID-19, 2021 NCT04332835
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
Li, 2020 ChiCTR2000029757
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
Rasheed, 2020
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
COV2-CP, 0 NCT04385043
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
CAPSID, 2021 NCT04433910
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
AlQahtani, 2020 NCT04356534
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
REMAP-CAP (plasma), 2021 NCT02735707
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
RECOVER, 2021 EudCT 2020-001632-10
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
PICP19 (Ray), 2020 CTRI/2020/05/025209
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
Bihariesingh-Sanchit (SuriCovid), 2021 ISRCTN18304314
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
Pouladzadeh, 2021 IRCT20200310046736N1
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
Sekine (PLACOVID), 2021 NCT04547660
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
Ray, 2022
convalescent plasma treatment vs. standard of care
COVID-19 severe or critically
Lu, 2020
corticosteroids vs. control
COVID-19 severe or critically
Tomasz, 2020
corticosteroids vs. control
COVID-19 severe or critically
Salton (Methylprednisolone), 2020
corticosteroids vs. control
COVID-19 severe or critically
Monreal, 2020
corticosteroids vs. corticosteroids
COVID-19 severe or critically
ChiCTR2000029386, 0 ChiCTR2000029386
corticosteroids vs. standard of care
COVID-19 severe or critically
CODEX, 2020 NCT04327401
corticosteroids vs. standard of care
COVID-19 severe or critically
CORTICOVIDHUGO, 0 NCT04359511
corticosteroids vs. standard of care
COVID-19 severe or critically
Raef, 2020
corticosteroids vs. standard of care
COVID-19 severe or critically
Jianfeng, 2020
corticosteroids vs. standard of care
COVID-19 severe or critically
CYCOV, 0 NCT04324528
cytokine adsorption vs. control
COVID-19 severe or critically
DEXA-COVID19, 2020 NCT04325061
dexamethasone vs. standard of care
COVID-19 severe or critically
CODEX (Tomazini), 2020 NCT04327401
dexamethasone vs. standard of care
COVID-19 severe or critically
Jamaati, 2021 IRCT20151227025726N1
dexamethasone vs. standard of care
COVID-19 severe or critically
Rashad, 2021 NCT04519385
dexamethasone vs. tocilizumab
COVID-19 severe or critically
Naik, 2021
dexamethasone vs. tocilizumab
COVID-19 severe or critically
COVID STEROID 2, 2021 NCT04509973
Dexamethasone 12mg vs. dexamethasone 6mg
COVID-19 severe or critically
Abuhasira, 2021 NCT04371978
DPP-4 inhibitor vs. standard of care
COVID-19 severe or critically
CORIMUNO19-ECU, 0 NCT04346797
eculizumab vs. standard of care
COVID-19 severe or critically
Lopardo, 2021 NCT04494984
equine polyclonal antibodies INM005 vs. placebo
COVID-19 severe or critically
Kocayigit H, 2020
favipiravir vs. lopinavir/ritonavir
COVID-19 severe or critically
ATTACC (Houston), 0 NCT04372589
heparin at therapeutic dose vs. control
COVID-19 severe or critically
ACTIV-4a (heparin), 0 NCT04505774
heparin at therapeutic dose vs. control
COVID-19 severe or critically
REMAP-CAP Anticoagulation, 0 NCT02735707
heparin at therapeutic dose vs. control
COVID-19 severe or critically
CAPE-COVID, 2020 NCT02517489
Hydrocortisone vs. placebo
COVID-19 severe or critically
Munch (COVID-STEROID), 2021 NCT04348305
Hydrocortisone vs. placebo
COVID-19 severe or critically
REMAP-CAP, fixed 7-day course, 2020 NCT02735707
Hydrocortisone vs. standard of care
COVID-19 severe or critically
REMAP-CAP, shock-dependent course, 2020 NCT02735707
Hydrocortisone vs. standard of care
COVID-19 severe or critically
Yu, 2020
hydroxychloroquine vs. control
COVID-19 severe or critically
HYDRA, 2020 NCT04315896
hydroxychloroquine vs. placebo
COVID-19 severe or critically
HYDRA (Hernandez-Cardenas), 2021 NCT04315896
hydroxychloroquine vs. placebo
COVID-19 severe or critically
Sarhan, 2022 NCT04779047
hydroxychloroquine vs. remdesivir
COVID-19 severe or critically
Mahevas, 2020
hydroxychloroquine vs. standard of care
COVID-19 severe or critically
REMAP-CAP-HCQ, 2020 NCT02735707
hydroxychloroquine vs. standard of care
COVID-19 severe or critically
Sarhan, 2022 NCT04779047
hydroxychloroquine vs. tocilizumab
COVID-19 severe or critically
AZIQUINE-ICU (A plus HCQ), 0 NCT04339816
hydroxychloroquine plus macrolides vs. placebo
COVID-19 severe or critically
Huang, 2020
hydroxychloroquine plus macrolides vs. standard of care
COVID-19 severe or critically
COVID-19-HBO, 0 NCT04327505
hyperbaric oxygen vs. standard of care
COVID-19 severe or critically
Kalil (ACTT-3), 2021 NCT04492475
IFN beta-1a vs. placebo
COVID-19 severe or critically
Davoudi-Monfared, 2020 IRCT20100228003449N2
IFN beta-1a vs. standard of care
COVID-19 severe or critically
Darazam (COVIFERON Interferon beta-1a), 2021 NCT04343768
IFN beta-1a vs. standard of care
COVID-19 severe or critically
Rahmani, 2020 IRCT20100228003449N2
IFN beta-1b vs. standard of care
COVID-19 severe or critically
Darazam (COVIFERON Interferon beta-1b), 2021 NCT04343768
IFN beta-1b vs. standard of care
COVID-19 severe or critically
COUNTER-COVID, 0 2020-001236-10
imatinib vs. placebo
COVID-19 severe or critically
Aman, 2021 Eudra 2020–001236–10
imatinib vs. placebo
COVID-19 severe or critically
Gharebaghi, 2020 IRCT20200501047259N1
immunoglobulin therapy vs. placebo
COVID-19 severe or critically
Tabarsi, 2020 IRCT20151227025726N2
immunoglobulin therapy vs. standard of care
COVID-19 severe or critically
Raman, 2021 CTRI/2020/06/026222
immunoglobulin therapy vs. standard of care
COVID-19 severe or critically
ACTIV-1 infliximab, 0 NCT04593940
infliximab vs. placebo
COVID-19 severe or critically
Kumar, 2021 CTRI/2020/05/024959
itolizumab vs. standard of care
COVID-19 severe or critically
Galan, 2021 RBR-8h7q82
ivermectin vs. chloroquine
COVID-19 severe or critically
Galan, 2021 RBR-8h7q82
ivermectin vs. hydroxychloroquine
COVID-19 severe or critically
Niaee (vs placebo), 2020 IRCT20200408046987N1
ivermectin vs. placebo
COVID-19 severe or critically
Camprubi, 2020
ivermectin vs. standard of care
COVID-19 severe or critically
Okumuş, 2020 NCT04646109
ivermectin vs. standard of care
COVID-19 severe or critically
NCT04347239, 0 NCT04347239
leronlimab vs. placebo
COVID-19 severe or critically
V.Lomakin (CORONA), 2021 NCT04397562
Levilimab vs. placebo
COVID-19 severe or critically
NCT00578825, 0 NCT00578825
lopinavir / ritonavir plus ribavirin vs. placebo
COVID-19 severe or critically
Cao, 2020 ChiCTR2000029308
lopinavir/ritonavir vs. standard of care
COVID-19 severe or critically
REMAP-CAP (lopinavir/ritonavir only), 2020 NCT02735707
lopinavir/ritonavir vs. standard of care
COVID-19 severe or critically
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 NCT02735707
Lopinavir/ritonavir plus hydroxychloroquine vs. standard of care
COVID-19 severe or critically
NCT04447469, 0 NCT04447469
mavrilimumab vs. placebo
COVID-19 severe or critically
Farahani, 2020 IRCT20200406046963N1
methylprednisolone vs. control
COVID-19 severe or critically
Steroids-SARI, 2020 NCT04244591
methylprednisolone vs. standard of care
COVID-19 severe or critically
Edalatifard, 2020 IRCT20200404046947N1
methylprednisolone vs. standard of care
COVID-19 severe or critically
Belhassen-Garc??a, 2021
methylprednisolone vs. tocilizumab
COVID-19 severe or critically
ENACOVID, 0 NCT04325633
naproxen, ibuprofen vs. standard of care
COVID-19 severe or critically
LIBA, 0 NCT04334629
naproxen, ibuprofen vs. standard of care
COVID-19 severe or critically
NCT04338802, 0 NCT04338802
nintedanib vs. standard of care
COVID-19 severe or critically
NCT04445623, 0 NCT04445623
P2Y12 inhibitors vs. placebo
COVID-19 severe or critically
Fragoso-Saavedra (PISCO), 2020 NCT04343963
pyridostigmine vs. placebo
COVID-19 severe or critically
CAP-China (Wang et al.), 2020 NCT04257656
remdesivir vs. placebo
COVID-19 severe or critically
CAPTOCOVID, 0 NCT04355429
Renin-angiotensin-system-acting agents vs. standard of care
COVID-19 severe or critically
RUXCOVID, 0 NCT04362137
ruxolitinib vs. placebo
COVID-19 severe or critically
DEVENT, 0 NCT04377620
ruxolitinib vs. placebo
COVID-19 severe or critically
Cao, 2020
ruxolitinib vs. vitamin C
COVID-19 severe or critically
SARPAC, 0 NCT04326920
sargramostim vs. standard of care
COVID-19 severe or critically
sarilumab Sanofi phase 3 US, 0 NCT04315298
sarilumab vs. control
COVID-19 severe or critically
ARI-RAF (Della-Torre), 2020
sarilumab vs. control
COVID-19 severe or critically
sarilumab Sanofi phase 3 outside US, 0
sarilumab vs. placebo
COVID-19 severe or critically
REMAP-CAP sarilumab, 2021 NCT02735707
sarilumab vs. standard of care
COVID-19 severe or critically
CORIMUNO-VIRO, 0 NCT04341870
sarilumab azithromycin hydroxychloroquine vs. sarilumab
COVID-19 severe or critically
Lescure (Sarilumab 400mg), 2021 NCT04327388
sarilumab high dose (400mg) vs. placebo
COVID-19 severe or critically
Lescure (Sarilumab 200mg), 2021 NCT04327388
sarilumab low dose (200mg) vs. placebo
COVID-19 severe or critically
Eslami, 2020 IRCT20200324046850N2
sofosbuvir and daclatasvir vs. ribavirin
COVID-19 severe or critically
INSPIRATION-S), 0
statins vs. control
COVID-19 severe or critically
STROMA-CoV2, 0 NCT04333368
stem cells vs. placebo
COVID-19 severe or critically
Shi, 2020 NCT04288102
stem cells vs. placebo
COVID-19 severe or critically
NCT04336254, 2020 NCT04336254
stem cells vs. standard of care
COVID-19 severe or critically
Shu, 2020 ChiCTR2000031494
stem cells vs. standard of care
COVID-19 severe or critically
TACROVID, 2021 NCT04341038
tacrolimus vs. standard of care
COVID-19 severe or critically
Singh (TD-0903 10mg), 2021 NCT04402866
TD-0903 10mg vs. placebo
COVID-19 severe or critically
Singh (TD-0903 1mg), 2021 NCT04402866
TD-0903 1mg vs. placebo
COVID-19 severe or critically
Singh (TD-0903 3mg), 2021 NCT04402866
TD-0903 3mg vs. placebo
COVID-19 severe or critically
Amra, 2021 IRCT20170207032444N3
thalidomide vs. standard of care
COVID-19 severe or critically
ChiCTR2000029806 (thymosin), 0 ChiCTR2000029806
thymosin vs. standard of care
COVID-19 severe or critically
Karakike (ESCAPE), 2021 NCT04339712
tocilizumab vs. anakinra
COVID-19 severe or critically
TOCI-RAF Study Group (Campochiaro), 2020
tocilizumab vs. control
COVID-19 severe or critically
Somers, 2020
tocilizumab vs. control
COVID-19 severe or critically
Mathilde, 2020
tocilizumab vs. control
COVID-19 severe or critically
Andrew, 2020
tocilizumab vs. control
COVID-19 severe or critically
Biran, 2020
tocilizumab vs. control
COVID-19 severe or critically
Klopfenstein, 2020
tocilizumab vs. control
COVID-19 severe or critically
Rashad, 2021 NCT04519385
tocilizumab vs. dexamethasone
COVID-19 severe or critically
CORON-ACT, 0 NCT04335071
tocilizumab vs. placebo
COVID-19 severe or critically
COVACTA (Rosas), 2020 NCT04320615
tocilizumab vs. placebo
COVID-19 severe or critically
NCT04377750 (HMO-0224-20), 0 NCT04377750
tocilizumab vs. placebo
COVID-19 severe or critically
Rosas (REMDACTA), 2021 NCT04409262
tocilizumab vs. placebo
COVID-19 severe or critically
Sarhan, 2022 NCT04779047
tocilizumab vs. remdesivir
COVID-19 severe or critically
ChiCTR2000030580, 0 ChiCTR2000030580
tocilizumab vs. standard of care
COVID-19 severe or critically
Rojas-Marte, 2020
tocilizumab vs. standard of care
COVID-19 severe or critically
Pereira, 2020
tocilizumab vs. standard of care
COVID-19 severe or critically
CORIMUNO-TOCI-1 (Group 1), 2020 NCT04331808
tocilizumab vs. standard of care
COVID-19 severe or critically
REMAP-CAP (tocilizumab), 2021 NCT02735707
tocilizumab vs. standard of care
COVID-19 severe or critically
Veiga, 2021 NCT04403685
tocilizumab vs. standard of care
COVID-19 severe or critically
Talaschian, 2021 IRCT20081027001411N4
tocilizumab vs. standard of care
COVID-19 severe or critically
Hamed, 2021
tocilizumab vs. standard of care
COVID-19 severe or critically
Karampitsakos, 2021
tocilizumab vs. standard of care
COVID-19 severe or critically
CORIMUNO-TOCI-ICU (Group 2), 2020 NCT04331808
tocilizumab vs. standard of care
COVID-19 severe or critically
MARIPOSA, 2021 NCT04363736
tocilizumab vs. tocilizumab
COVID-19 severe or critically
Belhassen-Garc??a, 2021
tocilizumab vs. tocilizumab
COVID-19 severe or critically
Sarhan, 2022 NCT04779047
tocilizumab vs. tocilizumab
COVID-19 severe or critically
PANAMO, 0 NCT04333420
vilobelimab (IFX-1) vs. standard of care
COVID-19 severe or critically
Zhang, 2020 NCT04264533
vitamin C vs. placebo
COVID-19 severe or critically
Jamali Moghadam Siahkali, 2021 IRCT20200411047025N1
vitamin C vs. standard of care
COVID-19 severe or critically
Kumari, 2020
vitamin C vs. standard of care
COVID-19 severe or critically
COVID-VIT-D, 2022 NCT04552951
Vitamin D vs. control
COVID-19 severe or critically